Skip to main content
Feature Story

Cover Story: Neutralizing HIV rebound

By Benjamin Boettner, Associate Editor

Neutralizing HIV rebound

Although antiretroviral therapies have transformed HIV infection into a chronically manageable disease, they have made little impact in reaching the latent viral reservoirs that are sources of disease rebound. Researchers at The Rockefeller University have found that broadly neutralizing antibodies against the HIV envelope protein, when given with viral inducers, can purge the reservoirs of virus and potentially eliminate the virus from its last bastion.1

Full Article

Today's Biotech & Pharma News

Room to Run?


    Neutralizing HIV rebound

    Rockefeller University researchers have shown that broadly neutralizing antibodies against HIV envelope proteins can knock the virus out of its latent reservoirs, thus opening an inroad to fully eliminating HIV from infected individuals.


    The FDA's push for better biomarkers

    The FDA is calling on stakeholders to help define a path for validating and approving biomarkers to enable their use in drug development.

  • Translational tidbits

    The FDA reviews the status of RNA sequencing; Serono builds on its lupus partnerships; Genomics England receives over £300 million ($500 million) in new investments; a roundup of recent public-private partnerships.


    Bad blood

    Whereas pharmacological approaches to treat sepsis have languished in the clinic, a microfluidic device developed by a Massachusetts team cleanses pathogens and endotoxins from blood and increases survival in rat models of sepsis.


    This Week in Therapeutics

    Countering MEK and BRAF inhibitor resistance in cancer by disrupting eIF4F; treating DMD with CRISPR-mediated genomic editing; inhibiting CRFR1 signaling to prevent hypoxia-induced cerebral edema; and more...


    This Week in Techniques

    A marmoset model of MERS-CoV infection; a fully functional thymus generated from reprogrammed fibroblasts; noninvasive methods for diagnosing Creutzfeldt-Jakob disease; and more...

Subscribe Now
Free Trial